Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
SNPX Synaptogenix	$9.31 -4.0%	$4.49	$1.84 ▼ $7.85	$12.94M	1.08	246,558 shs	267,982 shs
TLPH Talphera	$0.43 -0.9%	$0.49	$0.38 ▼ $1.19	$8.73M	-0.11	136,651 shs	128,916 shs
VRAX Virax Biolabs Group	$0.94 +1.6%	$0.93	$0.74 ▼ $9.00	$4.06M	1.65	1.73 million shs	53,043 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SNPX Synaptogenix	-6.60%	+18.23%	+127.05%	+358.39%	+118.36%
TLPH Talphera	-1.69%	-14.68%	-10.60%	-10.60%	-52.77%
VRAX Virax Biolabs Group	+5.86%	-0.28%	+5.83%	-7.30%	-28.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	0.3082 of 5 stars	0.0	2.0	0.0	0.0	3.8	0.0	0.0
TLPH Talphera	2.3664 of 5 stars	3.8	2.0	0.0	0.0	3.3	0.0	0.6
VRAX Virax Biolabs Group	3.0905 of 5 stars	3.5	3.0	0.0	0.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
SNPX Synaptogenix	0.00	N/A	N/A	N/A
TLPH Talphera	3.50	Strong Buy	$5.00	1,073.71% Upside
VRAX Virax Biolabs Group	3.00	Buy	$3.00	220.51% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
SNPX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A
TLPH Talphera	$650K	13.44	N/A	N/A	$0.47 per share	0.91
VRAX Virax Biolabs Group	$6.33K	641.94	N/A	N/A	$1.26 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	-$12.77M	-$10.08	N/A	∞	N/A	N/A	-115.28%	-58.31%	N/A
TLPH Talphera	-$13M	-$0.45	N/A	N/A	N/A	N/A	-130.28%	-59.25%	8/13/2025 (Estimated)
VRAX Virax Biolabs Group	-$6.06M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest VRAX, SNPX, PHXM, and TLPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	TLPH Talphera	-$0.1150	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	SNPX Synaptogenix	N/A	$0.04	N/A	$0.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
SNPX Synaptogenix	N/A	72.59	72.59
TLPH Talphera	N/A	3.11	3.11
VRAX Virax Biolabs Group	N/A	7.27	7.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PHXM PHAXIAM Therapeutics	0.40%
SNPX Synaptogenix	10.34%
TLPH Talphera	37.67%
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
PHXM PHAXIAM Therapeutics	1.94%
SNPX Synaptogenix	2.73%
TLPH Talphera	3.20%
VRAX Virax Biolabs Group	45.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
SNPX Synaptogenix	4	1.39 million	1.35 million	Not Optionable
TLPH Talphera	19	20.50 million	19.85 million	Optionable
VRAX Virax Biolabs Group	5	4.34 million	2.38 million	Not Optionable

VRAX, SNPX, PHXM, and TLPH Headlines

Recent News About These Companies

HC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy Recommendation

March 31, 2025 | msn.com

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

March 31, 2025 | benzinga.com

Virax Biolabs Launches Clinical Study on T Cell Dysfunction

March 18, 2025 | msn.com

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

March 18, 2025 | prnewswire.com

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

March 13, 2025 | prnewswire.com

Virax Biolabs to Present at 19th World Immune Regulation Meeting

March 5, 2025 | prnewswire.com

Virax Biolabs Aligns with US Health Department on Vaccine Transparency

February 25, 2025 | tipranks.com

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

February 25, 2025 | prnewswire.com

Cosmos Health expands distribution of Avian Influenza kits

January 23, 2025 | msn.com

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

January 23, 2025 | accessnewswire.comA

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

January 13, 2025 | accesswire.comA

Virax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?

December 19, 2024 | bovnews.comB

Virax Biolabs Announces Strategic Goals and Developments for 2025

December 18, 2024 | markets.businessinsider.com

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

December 17, 2024 | prnewswire.com

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

December 10, 2024 | prnewswire.com

Virax Biolabs Sees Asset Growth Amid Financial Loss

November 22, 2024 | markets.businessinsider.com

Virax Biolabs announces distribution agreement with Europa Biosite

October 23, 2024 | markets.businessinsider.com

Virax Biolabs Expands Reach with Europa Biosite Deal

October 23, 2024 | markets.businessinsider.com

Virax Biolabs Signs Distribution Agreement With Europa Biosite To Sell ImmuneSelect; Stock Up

October 23, 2024 | markets.businessinsider.com

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

October 23, 2024 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, SNPX, PHXM, and TLPH Company Descriptions

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 07/11/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Synaptogenix NASDAQ:SNPX

$9.31 -0.39 (-3.97%)

As of 07/16/2025

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Talphera NASDAQ:TLPH

$0.43 0.00 (-0.93%)

As of 02:38 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Virax Biolabs Group NASDAQ:VRAX

$0.94 +0.02 (+1.63%)

As of 02:36 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time